<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 16, 2026 at 8:39 pm by All in One SEO v5.0.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://helixgatebiotechreview.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Helixgate</title>
		<link><![CDATA[https://helixgatebiotechreview.com]]></link>
		<description><![CDATA[Helixgate]]></description>
		<lastBuildDate><![CDATA[Mon, 16 Nov 2026 20:25:19 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://helixgatebiotechreview.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://bioengineer.org/low-decisional-conflict-among-prostate-cancer-patients-seeking-germline-testing/]]></guid>
			<link><![CDATA[https://bioengineer.org/low-decisional-conflict-among-prostate-cancer-patients-seeking-germline-testing/]]></link>
			<title>Low Decisional Conflict Among Prostate Cancer Patients Seeking Germline Testing</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 20:25:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/new-chemotherapy-quality-of-life-scale-validated-for-breast-cancer-patients/]]></guid>
			<link><![CDATA[https://bioengineer.org/new-chemotherapy-quality-of-life-scale-validated-for-breast-cancer-patients/]]></link>
			<title>New Chemotherapy Quality of Life Scale Validated for Breast Cancer Patients</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 20:24:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/review-evaluates-integrin-alpha-9-beta-1-potential-in-cancer-theranostics-and-preclinical-limits/]]></guid>
			<link><![CDATA[https://bioengineer.org/review-evaluates-integrin-alpha-9-beta-1-potential-in-cancer-theranostics-and-preclinical-limits/]]></link>
			<title>Review Evaluates Integrin Alpha-9-Beta-1 Potential in Cancer Theranostics and Preclinical Limits</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 20:24:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/mendelian-randomization-study-links-specific-viral-antibodies-to-prostate-cancer-risk/]]></guid>
			<link><![CDATA[https://bioengineer.org/mendelian-randomization-study-links-specific-viral-antibodies-to-prostate-cancer-risk/]]></link>
			<title>Mendelian Randomization Study Links Specific Viral Antibodies to Prostate Cancer Risk</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 20:23:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/continuous-pediatric-antibiotic-infusions-reduce-preparation-time-without-altering-perceived-workload/]]></guid>
			<link><![CDATA[https://bioengineer.org/continuous-pediatric-antibiotic-infusions-reduce-preparation-time-without-altering-perceived-workload/]]></link>
			<title>Continuous Pediatric Antibiotic Infusions Reduce Preparation Time Without Altering Perceived Workload</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 20:23:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/china-overtakes-europe-healthcare-investing-sentiment]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/china-overtakes-europe-healthcare-investing-sentiment]]></link>
			<title>China overtakes Europe in healthcare investing sentiment</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 18:17:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/azs-alexion-extends-gmg-options-two-klygefa-approvals]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/azs-alexion-extends-gmg-options-two-klygefa-approvals]]></link>
			<title>AZ&#8217;s Alexion extends gMG options with two Klygefa approvals</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 18:17:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/gazyva-first-fda-cleared-drug-rare-disease-pmn]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/gazyva-first-fda-cleared-drug-rare-disease-pmn]]></link>
			<title>Gazyva is first FDA-cleared drug for rare disease pMN</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 18:17:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/lilly-strikes-again-buying-calytrix-15bn-deal]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/lilly-strikes-again-buying-calytrix-15bn-deal]]></link>
			<title>Lilly strikes again, buying Calytrix in $1.5bn deal</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 18:17:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/jj-cuts-33bn-deal-buy-eye-drug-developer-ollin]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/jj-cuts-33bn-deal-buy-eye-drug-developer-ollin]]></link>
			<title>J&amp;J cuts $3.3bn deal to buy eye drug developer Ollin</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 18:17:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/novo-s-investigational-cagrisema-glp-1-amylin-analog-demonstrated-21-average-weight-loss-lower-22684.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/novo-s-investigational-cagrisema-glp-1-amylin-analog-demonstrated-21-average-weight-loss-lower-22684.html]]></link>
			<title>Novo&#8217;s Investigational CagriSema, a GLP-1 and Amylin Analog, Demonstrated ~21% Average Weight Loss with Lower Doses in the REDEFINE 9 Trial</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 17:47:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/pots-phase-2-trial-shows-baloncibart-first-class-npr1-blocking-antibody-reduced-orthostatic-heart-22683.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/pots-phase-2-trial-shows-baloncibart-first-class-npr1-blocking-antibody-reduced-orthostatic-heart-22683.html]]></link>
			<title>POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 17:47:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.nature.com/articles/s41587-026-03344-5]]></guid>
			<link><![CDATA[https://www.nature.com/articles/s41587-026-03344-5]]></link>
			<title>A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 16:24:22 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://phys.org/news/2026-11-tool-tracks-unintended-crispr-effects.html]]></guid>
			<link><![CDATA[https://phys.org/news/2026-11-tool-tracks-unintended-crispr-effects.html]]></link>
			<title>New tool tracks unintended CRISPR edits and their effects in individual cells</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 15:52:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/artificial-intelligence/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/artificial-intelligence/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations/]]></link>
			<title>StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 06:51:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/summits-pd-1xvegf-rejected-by-fda-in-lung-cancer]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/summits-pd-1xvegf-rejected-by-fda-in-lung-cancer]]></link>
			<title>Summit&#8217;s PD-1xVEGF rejected by FDA in lung cancer</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 22:14:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/brodalumab-treatment-for-palmoplantar-pustulosis-linked-to-rare-pyoderma-gangrenosum-cases/]]></guid>
			<link><![CDATA[https://bioengineer.org/brodalumab-treatment-for-palmoplantar-pustulosis-linked-to-rare-pyoderma-gangrenosum-cases/]]></link>
			<title>Brodalumab Treatment for Palmoplantar Pustulosis Linked to Rare Pyoderma Gangrenosum Cases</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 18:13:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/low-palladium-zinc-oxide-boosts-antibiotic-removal-without-adding-water-toxicity/]]></guid>
			<link><![CDATA[https://bioengineer.org/low-palladium-zinc-oxide-boosts-antibiotic-removal-without-adding-water-toxicity/]]></link>
			<title>Low Palladium Zinc Oxide Boosts Antibiotic Removal Without Adding Water Toxicity</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 18:12:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.labiotech.eu/in-depth/bio-europe-2026/]]></guid>
			<link><![CDATA[https://www.labiotech.eu/in-depth/bio-europe-2026/]]></link>
			<title>Key takeaways from BIO-Europe 2026: European biotech has the science – but does it have the backing?</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 11:43:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/industry/generic-drug-user-fee-amendments/activities-report-generic-drug-program-fdara-title-viii-sections-807-and-805]]></guid>
			<link><![CDATA[http://www.fda.gov/industry/generic-drug-user-fee-amendments/activities-report-generic-drug-program-fdara-title-viii-sections-807-and-805]]></link>
			<title>Activities Report of the Generic Drug Program | FDARA Title VIII Sections 807 and 805</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 09:19:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/infectious-diseases/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/infectious-diseases/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital/]]></link>
			<title>How Vancomycin-Resistant Enterococcus Evolved in a Danish Hospital</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 22:13:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/arrowheads-ionis-problem-kyvernas-next-gen-end-and-more-biotech-earnings]]></guid>
			<link><![CDATA[https://www.biospace.com/business/arrowheads-ionis-problem-kyvernas-next-gen-end-and-more-biotech-earnings]]></link>
			<title>Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 16:36:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-delivery/pharmalogic-buys-lantheus-plant-to-build-transatlantic-radiopharmaceutical-cdmo]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-delivery/pharmalogic-buys-lantheus-plant-to-build-transatlantic-radiopharmaceutical-cdmo]]></link>
			<title>PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 16:36:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/job-trends/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies]]></guid>
			<link><![CDATA[https://www.biospace.com/job-trends/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies]]></link>
			<title>Cellectis could cut 70% of workforce in shift to in vivo therapies</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 16:36:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/emergency-preparedness-and-response/medical-countermeasure-mcm-issues/antimicrobial-resistance]]></guid>
			<link><![CDATA[http://www.fda.gov/emergency-preparedness-and-response/medical-countermeasure-mcm-issues/antimicrobial-resistance]]></link>
			<title>Antimicrobial Resistance</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 15:59:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/cancer-approvals/fda-approves-durvalumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/cancer-approvals/fda-approves-durvalumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer]]></link>
			<title>FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 12:07:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-policies-and-authorizations]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-policies-and-authorizations]]></link>
			<title>Section 804 Importation Program Policies and Authorizations</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 12:06:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-adults-primary-membranous-nephropathy]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-adults-primary-membranous-nephropathy]]></link>
			<title>FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 12:06:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.nature.com/articles/d41573-026-00181-8]]></guid>
			<link><![CDATA[https://www.nature.com/articles/d41573-026-00181-8]]></link>
			<title>Cancer vaccine development gets complicated</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 11:36:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.nature.com/articles/s41573-026-01583-4]]></guid>
			<link><![CDATA[https://www.nature.com/articles/s41573-026-01583-4]]></link>
			<title>From hope to adoption: an industry perspective on the maturation of new approach methodologies</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 11:36:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.nature.com/articles/s41573-026-01562-9]]></guid>
			<link><![CDATA[https://www.nature.com/articles/s41573-026-01562-9]]></link>
			<title>Immunogenicity risk assessment of novel modalities using new approach methodologies</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 11:36:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/regenerons-pots-antibody-curbs-heart-rate-spikes-teeing-up-phase-3-trial]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/regenerons-pots-antibody-curbs-heart-rate-spikes-teeing-up-phase-3-trial]]></link>
			<title>Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 11:05:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/windward-nets-175m-ipo-bringing-2026-biotech-debuts-to-35]]></guid>
			<link><![CDATA[https://www.biospace.com/business/windward-nets-175m-ipo-bringing-2026-biotech-debuts-to-35]]></link>
			<title>Windward nets $175M IPO, bringing 2026 biotech debuts to 35</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 11:05:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661604/windward-prices-ipo-rezera-postpones-its-offering-finance-report?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661604/windward-prices-ipo-rezera-postpones-its-offering-finance-report?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Windward prices IPO, Rezera postpones its offering: Finance Report</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 09:53:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661612/china-s-innovation-moment-sees-a-rise-in-first-in-class?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661612/china-s-innovation-moment-sees-a-rise-in-first-in-class?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>China’s innovation moment sees a rise in first in class</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 09:53:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661607/bio-s-plan-for-securing-america-s-biotech-century?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661607/bio-s-plan-for-securing-america-s-biotech-century?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>BIO’s plan for ‘securing America’s biotech century’</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 09:53:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/medline-updates-customers-and-patients-repair-and-replace-program-recall-medline-brand-beds-rails]]></guid>
			<link><![CDATA[http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/medline-updates-customers-and-patients-repair-and-replace-program-recall-medline-brand-beds-rails]]></link>
			<title>Medline Updates Customers and Patients on Repair and Replace Program for Recall of Medline Brand Beds, Rails, Mattresses and Accessories</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 06:00:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.labiotech.eu/podcast/inside-chiesis-2b-bet-on-arbors-next-generation-gene-editing/]]></guid>
			<link><![CDATA[https://www.labiotech.eu/podcast/inside-chiesis-2b-bet-on-arbors-next-generation-gene-editing/]]></link>
			<title>Inside Arbor’s CNS pipeline and next-generation gene editing</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 05:20:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/13/oura-acquisition-counsel-health-eli-lilly/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/13/oura-acquisition-counsel-health-eli-lilly/?utm_campaign=rss]]></link>
			<title>STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 04:00:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/pharmalot/2026/11/13/lilly-conflict-questions-dea-okays-takeda-narcolepsy-pill/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/pharmalot/2026/11/13/lilly-conflict-questions-dea-okays-takeda-narcolepsy-pill/?utm_campaign=rss]]></link>
			<title>STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 04:00:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/13/biotech-news-hhs-funding-for-research-into-ibogaine-for-ptsd/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/13/biotech-news-hhs-funding-for-research-into-ibogaine-for-ptsd/?utm_campaign=rss]]></link>
			<title>STAT+: HHS plans funding for research into ibogaine for PTSD</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 04:00:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.nature.com/articles/d41573-026-00179-2]]></guid>
			<link><![CDATA[https://www.nature.com/articles/d41573-026-00179-2]]></link>
			<title>How can gene therapy platforms be scaled up to treat thousands of rare diseases?</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 23:00:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs]]></link>
			<title>What&#8217;s New Related to Drugs</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 22:37:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs]]></link>
			<title>Notable Approvals | Drugs</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 22:34:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmavoice.com/news/why-biotech-companies-list-on-nasdaq/874486/]]></guid>
			<link><![CDATA[https://www.pharmavoice.com/news/why-biotech-companies-list-on-nasdaq/874486/]]></link>
			<title>How Nasdaq became biotech’s default exchange — and why the IPO comeback is testing its value</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 19:22:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmavoice.com/news/overton-fda-confirmation-biotech-nasdaq-pfizer/874558/]]></guid>
			<link><![CDATA[https://www.pharmavoice.com/news/overton-fda-confirmation-biotech-nasdaq-pfizer/874558/]]></link>
			<title>Overton’s iffy FDA confirmation; a slashed US IPO</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 19:22:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/infectious-diseases/reference-genomes-of-malaria-causing-plasmodium-parasites-completed/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/infectious-diseases/reference-genomes-of-malaria-causing-plasmodium-parasites-completed/]]></link>
			<title>Reference Genomes of Malaria-Causing Plasmodium Parasites Completed</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 18:51:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/multimedia/webinars/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave/]]></guid>
			<link><![CDATA[https://www.genengnews.com/multimedia/webinars/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave/]]></link>
			<title>Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 18:51:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/cancer-approvals/oncology-cancerhematologic-malignancies-approval-notifications]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/cancer-approvals/oncology-cancerhematologic-malignancies-approval-notifications]]></link>
			<title>Oncology (Cancer)/Hematologic Malignancies Approval Notifications</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 18:22:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://helixgatebiotechreview.com/]]></guid>
			<link><![CDATA[https://helixgatebiotechreview.com/]]></link>
			<title>Home</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 03:39:54 +0000]]></pubDate>
		</item>
				</channel>
</rss>
